{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:13:56Z","timestamp":1765887236399},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T00:00:00Z","timestamp":1281052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s11920-010-0140-8","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T01:34:43Z","timestamp":1280972083000},"page":"471-477","source":"Crossref","is-referenced-by-count":22,"title":["A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder"],"prefix":"10.1007","volume":"12","author":[{"given":"Dan J.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borwin","family":"Bandelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo F.","family":"Fontenelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Osser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray B.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"van Ameringen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,6]]},"reference":[{"key":"140_CR1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, edn 4","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Association; 1994."},{"key":"140_CR2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/da.20639","volume":"27","author":"DJ Stein","year":"2010","unstructured":"Stein DJ, Ruscio AM, Lee S, et al.: Subtyping social anxiety disorder in developed and developing countries. Depress Anxiety 2010, 27:390\u2013403.","journal-title":"Depress Anxiety"},{"key":"140_CR3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(08)60488-2","volume":"371","author":"MB Stein","year":"2008","unstructured":"Stein MB, Stein DJ: Social anxiety disorder. Lancet 2008, 371:1115\u20131125.","journal-title":"Lancet"},{"key":"140_CR4","doi-asserted-by":"crossref","unstructured":"Beard C, Moitra E, Weisberg RB, et al.: Characteristics and predictors of social phobia course in a longitudinal study of primary-care patients. Depress Anxiety 2010 Feb 23 (Epub ahead of print).","DOI":"10.1002\/da.20676"},{"key":"140_CR5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.euroneuro.2005.04.002","volume":"15","author":"L Fehm","year":"2005","unstructured":"Fehm L, Pelissolo A, Furmark T, et al.: Size and burden of social phobia in Europe. Eur Neuropsychopharmacol 2005, 15:453\u2013462.","journal-title":"Eur Neuropsychopharmacol"},{"key":"140_CR6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S1461145703003791","volume":"6","author":"C Blanco","year":"2003","unstructured":"Blanco C, Raza MS, Schneier FR, et al.: The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 2003, 6:427\u2013442.","journal-title":"Int J Neuropsychopharmacol"},{"key":"140_CR7","first-page":"CD001206","volume":"4","author":"DJ Stein","year":"2004","unstructured":"Stein DJ, Ipser JC, Balkom AJ: Pharmacotherapy for social anxiety disorder. Cochrane Database Syst Rev 2004, 4:CD001206.","journal-title":"Cochrane Database Syst Rev"},{"key":"140_CR8","first-page":"CD005473","volume":"4","author":"JC Ipser","year":"2006","unstructured":"Ipser JC, Carey P, Dhansay Y, et al.: Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev 2006, 4:CD005473.","journal-title":"Cochrane Database Syst Rev"},{"key":"140_CR9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"B Bandelow","year":"2008","unstructured":"\u2022 Bandelow B, Zohar J, Hollander E, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders\u2014first revision. World J Biol Psychiatry 2008, 9:248\u2013312. This paper provides a systematic review of the literature on the pharmacotherapy of anxiety disorders, as well as guidelines for clinicians.","journal-title":"World J Biol Psychiatry"},{"key":"140_CR10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","volume":"19","author":"DS Baldwin","year":"2005","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, et al.: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005, 19:567\u2013596.","journal-title":"J Psychopharmacol"},{"issue":"Suppl 2","key":"140_CR11","first-page":"1","volume":"51","author":"RP Swinson","year":"2006","unstructured":"Swinson RP, Antony MM, Bleau PB, et al.: Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry 2006, 51(Suppl 2):1\u201392.","journal-title":"Can J Psychiatry"},{"key":"140_CR12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1185\/135525701317094368","volume":"7","author":"DJ Stein","year":"2001","unstructured":"Stein DJ, Kasper S, Matsunaga H, et al.: Pharmacotherapy of social anxiety disorder: an algorithm for primary care\u20142001. Prim Care Psychiatry 2001, 7:107\u2013110.","journal-title":"Prim Care Psychiatry"},{"key":"140_CR13","volume-title":"Evidence-Based Psychopharmacology","author":"DJ Stein","year":"2005","unstructured":"Stein DJ, Lerer B, Stahl S: Evidence-Based Psychopharmacology. Cambridge, United Kingdom: Cambridge University Press; 2005."},{"key":"140_CR14","volume-title":"Stein DJ, Jobson KO: Textbook of Treatment Algorithms in Psychopharmacology","author":"J Fawcett","year":"1999","unstructured":"Fawcett J, Stein DJ, Jobson KO: Textbook of Treatment Algorithms in Psychopharmacology. Chichester, United Kingdom: John Wiley & Sons; 1999."},{"key":"140_CR15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/archpsyc.1993.01820180085009","volume":"50","author":"AJ Rush","year":"2001","unstructured":"Rush AJ: Clinical practice guidelines: good news, bad news, or no news? Arch Gen Psychiatry 2001, 50:483\u2013490.","journal-title":"Arch Gen Psychiatry"},{"key":"140_CR16","first-page":"13","volume":"46","author":"AM Letamendi","year":"2009","unstructured":"Letamendi AM, Chavira DA, Stein MB: Issues in the assessment of social phobia: a review. Isr J Psychiatry Relat Sci 2009, 46:13\u201324.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"140_CR17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00023210-200519050-00002","volume":"19","author":"JE Muller","year":"2005","unstructured":"Muller JE, Koen L, Seedat S, et al.: Social anxiety disorder: current treatment recommendations. CNS Drugs 2005, 19:377\u2013391.","journal-title":"CNS Drugs"},{"key":"140_CR18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archgenpsychiatry.2010.11","volume":"67","author":"C Blanco","year":"2010","unstructured":"Blanco C, Heimberg RG, Schneier FR, et al.: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010, 67:286\u2013295.","journal-title":"Arch Gen Psychiatry"},{"key":"140_CR19","first-page":"62","volume":"46","author":"JS Singh","year":"2009","unstructured":"Singh JS, Hope DA: Cognitive-behavioral approaches to the treatment of social anxiety disorder. Isr J Psychiatry Relat Sci 2009, 46:62\u201369.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"140_CR20","first-page":"34","volume":"46","author":"CA Hitchcock","year":"2009","unstructured":"Hitchcock CA, Chavira DA, Stein MB: Recent findings in social phobia among children and adolescents. Isr J Psychiatry Relat Sci 2009, 46:34\u201344.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"140_CR21","doi-asserted-by":"crossref","unstructured":"Ipser JC, Stein DJ, Hawkridge S, et al.: Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2009, 3:CD005170.","DOI":"10.1002\/14651858.CD005170.pub2"},{"key":"140_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3928\/0048-5713-19990501-10","volume":"29","author":"DN Osser","year":"1999","unstructured":"Osser DN, Renner JA Jr, Bayog R: Algorithms for the pharmacotherapy of anxiety disorders in patients with chemical abuse and dependence. Psychiatr Ann 1999, 29:285\u2013301.","journal-title":"Psychiatr Ann"},{"key":"140_CR23","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2009.07.009","volume":"31","author":"M Tuccori","year":"2009","unstructured":"Tuccori M, Testi A, Antonioli L, et al.: Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic\/noradrenergic antidepressants during pregnancy: a review. Clin Ther 2009, 31:1426\u20131453.","journal-title":"Clin Ther"},{"key":"140_CR24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","volume":"22","author":"KA Kobak","year":"2002","unstructured":"Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ: Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002, 22:257\u2013262.","journal-title":"J Clin Psychopharmacol"},{"key":"140_CR25","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archpsyc.61.10.1005","volume":"61","author":"JRT Davidson","year":"2004","unstructured":"Davidson JRT, Foa EB, Huppert JD, et al.: Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004, 61:1005\u20131013.","journal-title":"Arch Gen Psychiatry"},{"key":"140_CR26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","volume":"49","author":"MR Liebowitz","year":"1992","unstructured":"Liebowitz MR, Schneier F, Campeas R, et al.: Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992, 49:290\u2013300.","journal-title":"Arch Gen Psychiatry"},{"key":"140_CR27","first-page":"423","volume":"13","author":"JRT Davidson","year":"1993","unstructured":"Davidson JRT, Potts N, Richichi E, et al.: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993, 13:423\u2013428.","journal-title":"J Clin Psychopharmacol"},{"key":"140_CR28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s002130100880","volume":"158","author":"DJ Stein","year":"2001","unstructured":"Stein DJ, Stein MB, Goodwin W, Hunter B: The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and less generalized social anxiety disorder. Psychopharmacology (Berl) 2001, 158:267\u2013272.","journal-title":"Psychopharmacology (Berl)"},{"key":"140_CR29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","volume":"19","author":"M Lader","year":"2004","unstructured":"Lader M, Stender K, B\u00fcrger V, Nil R: The efficacy and tolerability of escitalopram in the short- and long-term treatment of social anxiety disorder: a randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004, 19:241\u2013248.","journal-title":"Depress Anxiety"},{"key":"140_CR30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00004850-200207000-00002","volume":"17","author":"DJ Stein","year":"2002","unstructured":"Stein DJ, Cameron A, Amrein R, Montgomery SA: Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 2002, 17:161\u2013170.","journal-title":"Int Clin Psychopharmacol"},{"key":"140_CR31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00004850-199606003-00013","volume":"11S","author":"D Nutt","year":"1996","unstructured":"Nutt D, Montgomery SA: Moclobemide in the treatment of social phobia. Int Clin Psychopharmacol 1996, 11S:77\u201382.","journal-title":"Int Clin Psychopharmacol"},{"key":"140_CR32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1185\/03007998409109561","volume":"9","author":"LF Allsopp","year":"1984","unstructured":"Allsopp LF, Cooper GL, Poole PH: Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Curr Med Res Opin 1984, 9:64\u201370.","journal-title":"Curr Med Res Opin"},{"key":"140_CR33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/030006057700500605","volume":"5","author":"G Beaumont","year":"1977","unstructured":"Beaumont G: A large open multicenter trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res 1977, 5:116\u2013123.","journal-title":"J Int Med Res"},{"key":"140_CR34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00004714-199810000-00004","volume":"18","author":"KM Connor","year":"1998","unstructured":"Connor KM, Davidson JRT, Potts NLS, et al.: Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998, 18:373\u2013378.","journal-title":"J Clin Psychopharmacol"},{"key":"140_CR35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","volume":"19","author":"AC Pande","year":"1999","unstructured":"Pande AC, Davidson JR, Jefferson JW, et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999, 19:341\u2013348.","journal-title":"J Clin Psychopharmacol"},{"key":"140_CR36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000117423.05703.e7","volume":"24","author":"AC Pande","year":"2004","unstructured":"Pande AC, Feltner DE, Jefferson JW, et al.: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004, 24:141\u2013149.","journal-title":"J Clin Psychopharmacol"},{"key":"140_CR37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08m04949gre","volume":"71","author":"MB Stein","year":"2010","unstructured":"Stein MB, Ravindran LN, Simon NM, et al.: Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry 2010, 71:627\u2013631.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 6","key":"140_CR38","first-page":"12","volume":"63","author":"DJ Stein","year":"2002","unstructured":"Stein DJ, Westenberg H, Liebowitz MR: Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J Clin Psychiatry 2002, 63(Suppl 6):12\u201319.","journal-title":"J Clin Psychiatry"},{"key":"140_CR39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/026988110201600412","volume":"16","author":"SD Barnett","year":"2002","unstructured":"Barnett SD, Kramer ML, Casat CD, et al.: Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002, 16:365\u2013368.","journal-title":"J Psychopharmacol"},{"key":"140_CR40","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.pnpbp.2007.06.027","volume":"31","author":"S Vaishnavi","year":"2007","unstructured":"Vaishnavi S, Alamy S, Zhang W, et al.: Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1464\u20131469.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"140_CR41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4088\/JCP.v60n1203","volume":"60","author":"S Pallanti","year":"1999","unstructured":"Pallanti S, Quercioli L, Rossi A, Pazzagli A: The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. J Clin Psychiatry 1999, 60:819\u2013823.","journal-title":"J Clin Psychiatry"},{"key":"140_CR42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1192\/bjp.176.4.379","volume":"176","author":"KM Connor","year":"2000","unstructured":"Connor KM, Davidson JRT, Churchill LE, et al.: Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale. Br J Psychiatry 2000, 176:379\u2013386.","journal-title":"Br J Psychiatry"},{"key":"140_CR43","unstructured":"Liebowitz MR: Social phobia. In Modern Problems of Pharmacopsychiatry. Edited by Ban TA, Pichot P, Poldinger W. Basel, Switzerland: Karger; 1987."},{"key":"140_CR44","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.v67n0914","volume":"67","author":"B Bandelow","year":"2006","unstructured":"Bandelow B, Baldwin DS, Dolberg OT, et al.: What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006, 67:1428\u20131434.","journal-title":"J Clin Psychiatry"},{"key":"140_CR45","first-page":"244","volume":"65","author":"S Seedat","year":"2004","unstructured":"Seedat S, Stein MB: Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004, 65:244\u2013248.","journal-title":"J Clin Psychiatry"},{"key":"140_CR46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1745-0179-2-35","volume":"2","author":"S Pallanti","year":"2006","unstructured":"Pallanti S, Quercioli L: Resistant social anxiety disorder response to escitalopram. Clin Pract Epidemiol Ment Health 2006, 2:35.","journal-title":"Clin Pract Epidemiol Ment Health"},{"issue":"Suppl 2","key":"140_CR47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004850-200008002-00004","volume":"15","author":"GJH Linden van der","year":"2000","unstructured":"van der Linden GJH, Stein DJ, van Balkom AJLM: The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000, 15(Suppl 2):15\u201324.","journal-title":"Int Clin Psychopharmacol"},{"key":"140_CR48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4088\/JCP.v63n0211","volume":"63","author":"DJ Stein","year":"2002","unstructured":"Stein DJ, Stein MB, Pitts CD, et al.: Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002, 63:152\u2013155.","journal-title":"J Clin Psychiatry"},{"key":"140_CR49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1017\/S1092852900006933","volume":"8","author":"M Ameringen Van","year":"2003","unstructured":"Van Ameringen M, Allgulander C, Bandelow B, et al.: WCA recommendations for the long-term treatment of social phobia. CNS Spectr 2003, 8:40\u201352.","journal-title":"CNS Spectr"},{"key":"140_CR50","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-199709000-00001","volume":"12","author":"M Versiani","year":"1997","unstructured":"Versiani M, Amrein R, Montgomery SA: Social phobia: long-term treatment outcome and prediction of response\u2014a moclobemide study. Int Clin Psychopharmacol 1997, 12:239\u2013254.","journal-title":"Int Clin Psychopharmacol"},{"key":"140_CR51","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archgenpsychiatry.2010.11","volume":"67","author":"C Blanco","year":"2010","unstructured":"Blanco C, Heimberg RG, Schneier FR, et al.: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010, 67:286\u2013295.","journal-title":"Arch Gen Psychiatry"},{"key":"140_CR52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-0327(96)00030-4","volume":"39","author":"M Ameringen van","year":"1996","unstructured":"van Ameringen M, Mancini C, Wilson C: Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996, 39:115\u2013121.","journal-title":"J Affect Disord"},{"key":"140_CR53","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4088\/JCP.v58n0405","volume":"58","author":"IM Vliet van","year":"1997","unstructured":"van Vliet IM, den Boer JA, Westenberg HG, et al.: Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997, 58:164\u2013168.","journal-title":"J Clin Psychiatry"},{"key":"140_CR54","first-page":"244","volume":"65","author":"S Seedat","year":"2004","unstructured":"Seedat S, Stein MB: Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004, 65:244\u2013248.","journal-title":"J Clin Psychiatry"},{"key":"140_CR55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4088\/JCP.v67n0307","volume":"67","author":"NM Simon","year":"2006","unstructured":"Simon NM, Hoge EA, Fischmann D, et al.: An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 2006, 67:381\u2013385.","journal-title":"J Clin Psychiatry"},{"key":"140_CR56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-200501000-00002","volume":"20","author":"JJ Worthington III","year":"2005","unstructured":"Worthington JJ III, Kinrys G, Wygant LE, et al.: Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005, 20:9\u201311.","journal-title":"Int Clin Psychopharmacol"},{"key":"140_CR57","first-page":"767","volume":"31","author":"JE Kelsey","year":"1995","unstructured":"Kelsey JE: Venlafaxine in social phobia. Psychopharmacol Bull 1995, 31:767\u2013771.","journal-title":"Psychopharmacol Bull"},{"key":"140_CR58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-199907000-00006","volume":"14","author":"AC Altamura","year":"1999","unstructured":"Altamura AC, Pioli R, Vitto M, et al.: Venlafaxine in social phobia: a study in selective serotonin reuptake non-responders. Int Clin Psychopharmacol 1999, 14:239\u2013245.","journal-title":"Int Clin Psychopharmacol"},{"key":"140_CR59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/08039480310002110","volume":"57","author":"TF Aarre","year":"2003","unstructured":"Aarre TF: Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord J Psychiatry 2003, 57:313\u2013315.","journal-title":"Nord J Psychiatry"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-010-0140-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-010-0140-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-010-0140-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:41:16Z","timestamp":1559436076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-010-0140-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,6]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1007\/s11920-010-0140-8","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,6]]}}}